Sunday, December 3, 2023
| Isolate (Patient, Source) | APIStrep† | STR Rapid ID32† | Agglutination with Group Serum Specimens | VITEK2 GP-ID† | AccuProbe |
|---|---|---|---|---|---|
| Hum1 (patient 1, CSF) | 0063607 (99.9% S. zooepidemicus) |
15412061151 (99.9% S. zooepidemicus) |
Group C | Not done | Not done |
| Hum2 (patient 2, blood) | Not done | 15412061151 (99.9% S. zooepidemicus) |
Group C | 053450364317451 (99% S. zooepidemicus) |
Streptococcus agalactiae‡ |
| Hum3 (patient 3, abdominal aortic wall) |
Not done | 15512061111 (99.9% S. zooepidemicus) |
Group C | Not done | Not done |
*ISLAB, Eastern Finland Laboratory Centre Joint authority Enterprise; CSF, cerebral spinal fluid.
†bioMérieux, Marcy l’Etoile, France.
‡S. agalactiae (315,588 reflective light units, the reference range below 50,000 reflective light units). S. agalactiae and S. zooepidemicus are known to cross-react in the AccuProbe Group B Streptococcus Culture ID Test (Gen-Probe, San Diego, CA, USA).
| Isolate ID no. | Origin | Year | Stable | MLST sequence type | SzP type | SzP GenBank accession no. |
|---|---|---|---|---|---|---|
| Hum1 | Patient 1, blood | 2011 | A | ST-10 | I | AF519489 |
| Hum2 | Patient 2, blood | 2011 | H | ST-10 | I | AF519489 |
| Hum3 | Patient 3, aortic wall | 2011 | Not done | ST-209 | VII | AF519488 |
| 642/11 | Horse, nasal swab, nonclinical | 2011 | A | ST-147 | IV | AF519482 |
| 645/11 | Horse, nasal swab, nonclinical | 2011 | A | ST-175 | II | AFKC287220† |
| 646/11 | Horse, nasal swab, nonclinical | 2011 | A | ST-66 | V | AFKC287221† |
| 647/11 | Horse, nasal swab, nonclinical | 2011 | A | ST-175 | II | AFKC287220† |
| 648/11 | Horse, nasal swab, nonclinical | 2011 | A | ST-10 | I | AF519489 |
| 744/11 | Horse, nasal swab, nonclinical‡ | 2011 | C | ST-80 | VIII | U04620 |
| 1128/11 | Horse, foal, sepsis | 2011 | B | ST-5 | VI | AFKC287222† |
| 627/11 | Horse, nasal swab, nonclinical‡ | 2011 | C | ST-115 | III | AF519478 |
| 6939/10 | Horse, nasal swab, nonclinical‡ | 2010 | D | ST-201 | VII | AF519488 |
| 8110/09 | Horse, synovial fluid (arthritis) | 2009 | E | ST-299† | III | AF519478 |
| 7723/09 | Horse, foal, tracheal fluid, respiratory infection§ | 2009 | F | ST-XX†¶ | III | AF519478 |
*ID, identification; MLST, multilocus sequence typing.
†Not previously described.
‡The samples were collected for screening of S. equi subsp. equi, but S. equi subsp. zooepidemicus was identified.
§Co-infection with Pasteurella sp. and S. suis.
¶Recorded in the PubMLST database: 8 (arcC)–52 (nrdE)–2 (proS)–14 (spi)–1 (tdk)–22 (tpi)–n/a (yqiL).
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor and Residency Director, Department of Family Medicine, University of California, Irvine
This activity is intended for infectious disease specialists and other physicians who care for patients with possible Sez infection.
The goal of this activity is to analyze the clinical and molecular characteristics of Streptococcus equi zooepidemicus.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor and Residency Director, Department of Family Medicine, University of California, Irvine
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 6/28/2013
Valid for credit through: 6/28/2014, 11:59 PM EST
processing....
Streptococcus equi subspecies zooepidemicus (S. zooepidemicus) is a zoonotic pathogen for persons in contact with horses. In horses, S. zooepidemicus is an opportunistic pathogen, but human infections associated with S. zooepidemicus are often severe. Within 6 months in 2011, 3 unrelated cases of severe, disseminated S. zooepidemicus infection occurred in men working with horses in eastern Finland. To clarify the pathogen’s epidemiology, we describe the clinical features of the infection in 3 patients and compare the S. zooepidemicus isolates from the human cases with S. zooepidemicus isolates from horses. The isolates were analyzed by using pulsed-field gel electrophoresis, multilocus sequence typing, and sequencing of the szP gene. Molecular typing methods showed that human and equine isolates were identical or closely related. These results emphasize that S. zooepidemicus transmitted from horses can lead to severe infections in humans. As leisure and professional equine sports continue to grow, this infection should be recognized as an emerging zoonosis.
Streptococcus equi subspecies zooepidemicus (S. zooepidemicus) is a β-hemolytic, Lancefield group C streptococcal bacterium. S. zooepidemicus is considered an opportunistic commensal in horses,[1–3] but it may also cause infections in other domestic animals such as cattle, sheep, goats, pigs, dogs, and cats.[4–10] Another subspecies of the same genus, Streptococcus equi subsp. equi (S. equi), causes strangles, the highly contagious and serious disease in horses.[1,11,12]
S. zooepidemicus shares >98% DNA sequence homology with S. equi[1] and >80% DNA sequence homology with Streptococcus pyogenes,[13] a Lancefield group A streptococcus and major human pathogen. Although considered an opportunistic pathogen, S. zooepidemicus shares important virulence factors with both S. equi and S. pyogenes such as the M-like proteins, superantigens (sAgs), and the presence of a hyaluronic acid capsule in certain strains. The variable M-protein, located on the surface of S. pyogenes, can be used to differentiate S. pyogenes strains serologically where the M1 serotype is associated with invasive disease in humans.[14] The M-like, cell-wall–anchored surface protein SzP, found in all strains of S. zooepidemicus, is essential for the pathogenesis of the disease, at least in horses, where it binds fibrinogen and exhibits antiphagocytic activity that impairs with host protection. The sAgs SeeH, SeeI, SeeL, and SeeM found in S. equi share 96%–99% amino acid sequence homology with S. pyogenes sAgs SpeH, SpeI, SpeL, and SpeM.[15] However, few investigated strains of S. zooepidemicus contain homologs to these sAgs. Instead, novel sAgs (SzeF, SzeN, and SzeP) have been identified in certain strains, sharing 34%–59% homology with SpeH, SpeM, and SpeL of S. pyogenes.[16]
S. zooepidemicus has seldom been isolated from humans. Surprisingly, most published data on humans go back to the latter part of the 1980s.[17] Occasional human infection was reported as a result of the consumption of homemade cheese or unpasteurized milk from cows with mastitis.[17] In humans, S. zooepidemicus may cause glomerulonephritis and rheumatic fever, which are known sequelae of S. pyogenes (group A) infections.[18] Meningitis and purulent arthritis have also been reported.[19,20]
S. zooepidemicus displays a wide genetic variation between different isolates.[13,21–23] The sequence of the SzP protein gene (szP) has been shown to vary greatly between different strains of S. zooepidemicus,[24–26] and the variable regions of szP can be used to genetically differentiate strains within the subspecies.[27–29] Pulsed-field gel electrophoresis (PFGE) is a DNA-based typing technique that is highly discriminatory and has been used in epidemiologic investigations of S. zooepidemicus outbreaks.[30,31]
Multilocus sequence typing (MLST) is a method for characterization of bacterial isolates by comparing sequences of several gene fragments. Webb et al.[22] developed a MLST protocol for S. zooepidemicus consisting of 7 housekeeping genes. Obtained sequences are compared to previously deposited sequences, and a sequence type (ST) is assigned from the online PubMLST S. zooepidemicus database (http://pubmlst.org/szooepidemicus) developed by Jolley et al.[32]
Within a 6-month period, through our routine practice, we found 3 cases of severe disseminated disease in humans caused by S. zooepidemicus. The purpose of this study was to 1) characterize the clinical presentation of the disease caused by S. zooepidemicus, 2) microbiologically characterize the isolated strains, and 3) identify clonality of human isolates for comparison to equine isolates from contact horse stables and other horse farms of the surrounding area.
